High‐ and low‐dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: A randomized control trial
While the primary analyses did not find evidence that topiramate decreases drinking and smoking behavior, likely influenced by a high attrition rate and poor medication adherence, exploratory repeated measures analyses suggest that topiramate 250 mg reduces drinking behavior and that both the 125 mg and 250 mg doses reduce smoking behavior. Future studies that maximize treatment adherence are needed to more definitively determine whether topiramate is an effective treatment for AUD and TUD.
Authors
- Maher Karam‐Hage (ORCID: https://orcid.org/0000-0001-5883-4436)
- Robert M. Anthenelli (ORCID: https://orcid.org/0000-0002-6612-1126)
- Paul M. Cinciripini (ORCID: https://orcid.org/0000-0003-2877-9928)
- Jason D. Robinson (ORCID: https://orcid.org/0000-0002-1588-9637)
- George Kypriotakis (ORCID: https://orcid.org/0000-0002-2011-4545)
- Nassima Ait‐Daoud Tiouririne (ORCID: https://orcid.org/0000-0002-0604-8377)
- Yong Cui (ORCID: https://orcid.org/0000-0003-0218-271X)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of California San Diego (US)
- University of Virginia (US)
Publication Details
- Journal
- Alcohol Clinical and Experimental Research
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1111/acer.70193
- Primary Topic
- Smoking Behavior and Cessation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute